200 related articles for article (PubMed ID: 27599042)
1. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.
Jonsson M; Ragnum HB; Julin CH; Yeramian A; Clancy T; Frikstad KM; Seierstad T; Stokke T; Matias-Guiu X; Ree AH; Flatmark K; Lyng H
Br J Cancer; 2016 Oct; 115(8):929-939. PubMed ID: 27599042
[TBL] [Abstract][Full Text] [Related]
2. DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions.
Stewart GD; Nanda J; Katz E; Bowman KJ; Christie JG; Brown DJ; McLaren DB; Riddick AC; Ross JA; Jones GD; Habib FK
Biochem Pharmacol; 2011 Jan; 81(2):203-10. PubMed ID: 20888325
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; RodrÃguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
4. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
5. Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro.
Forde JC; Maginn EN; McNamara G; Martin LM; Campiani G; Williams DC; Zisterer D; McElligott AM; Lawler M; Lynch TH; Hollywood D; Marignol L
Cancer Biol Ther; 2011 Feb; 11(4):421-8. PubMed ID: 21131779
[TBL] [Abstract][Full Text] [Related]
6. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition.
Hutt DM; Roth DM; Vignaud H; Cullin C; Bouchecareilh M
PLoS One; 2014; 9(8):e106224. PubMed ID: 25166596
[TBL] [Abstract][Full Text] [Related]
8. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
Munshi A; Tanaka T; Hobbs ML; Tucker SL; Richon VM; Meyn RE
Mol Cancer Ther; 2006 Aug; 5(8):1967-74. PubMed ID: 16928817
[TBL] [Abstract][Full Text] [Related]
9. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
[TBL] [Abstract][Full Text] [Related]
10. Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation.
Souchek JJ; Baine MJ; Lin C; Rachagani S; Gupta S; Kaur S; Lester K; Zheng D; Chen S; Smith L; Lazenby A; Johansson SL; Jain M; Batra SK
Br J Cancer; 2014 Sep; 111(6):1139-49. PubMed ID: 25025965
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
Lee JH; Choy ML; Ngo L; Foster SS; Marks PA
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14639-44. PubMed ID: 20679231
[TBL] [Abstract][Full Text] [Related]
12. Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity.
Konsoula Z; Cao H; Velena A; Jung M
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1541-8. PubMed ID: 21277099
[TBL] [Abstract][Full Text] [Related]
13. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Zhou X; Yang XY; Popescu NC
Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
[TBL] [Abstract][Full Text] [Related]
15. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
Oh ET; Park MT; Choi BH; Ro S; Choi EK; Jeong SY; Park HJ
Invest New Drugs; 2012 Apr; 30(2):435-42. PubMed ID: 20978925
[TBL] [Abstract][Full Text] [Related]
16. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
17. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
Laurenzana A; Balliu M; Cellai C; Romanelli MN; Paoletti F
PLoS One; 2013; 8(3):e58267. PubMed ID: 23469273
[TBL] [Abstract][Full Text] [Related]
19. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
Chun SG; Zhou W; Yee NS
Cancer Biol Ther; 2009 Jul; 8(14):1328-39. PubMed ID: 19421011
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression.
Jeon HW; Lee YM
Mol Cancer Ther; 2010 May; 9(5):1361-70. PubMed ID: 20442303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]